Oral iron chelating drugs: coming but not yet ready for clinical use.
作者信息
Hershko C
出版信息
Br Med J (Clin Res Ed). 1988 Apr 16;296(6629):1081-2. doi: 10.1136/bmj.296.6629.1081.
Abstract
摘要
相似文献
1
Oral iron chelating drugs: coming but not yet ready for clinical use.口服铁螯合剂药物：即将问世但尚未准备好用于临床。
Br Med J (Clin Res Ed). 1988 Apr 16;296(6629):1081-2. doi: 10.1136/bmj.296.6629.1081.
2
An oral treatment for iron overload in thalassemia?
Hepatology. 1996 Feb;23(2):380-2. doi: 10.1002/hep.510230229.
3
Combining two orally active iron chelators for thalassemia.
Ann Hematol. 2010 Nov;89(11):1177-8. doi: 10.1007/s00277-010-0933-1. Epub 2010 Mar 10.
4
5
Deferiprone for thalassaemia.
Lancet. 2000 Oct 21;356(9239):1444-5. doi: 10.1016/S0140-6736(05)74089-7.
6
Report on the proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
Hemoglobin. 2006;30(1):63-8. doi: 10.1080/03630260500454709.
7
Deferasirox in thalassemia patients with end-stage renal disease.地拉罗司用于终末期肾病地中海贫血患者。
Am J Hematol. 2016 Oct;91(10):E456-7. doi: 10.1002/ajh.24457. Epub 2016 Jul 14.
8
Iron chelating drugs.铁螯合剂药物。
Br Med J (Clin Res Ed). 1988 Jun 11;296(6637):1672-3. doi: 10.1136/bmj.296.6637.1672-c.
9
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.在铁过载的地中海贫血患者中使用1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮（L1）进行口服铁螯合治疗。
Bone Marrow Transplant. 1993;12 Suppl 1:9-11.
10
[Patient compliance in iron-chelating therapy of beta-thalassemia major].
Minerva Pediatr. 1983 May 31;35(10):489-93.
引用本文的文献
1
Transferrin iron starvation therapy for lethal bacterial and fungal infections.转铁蛋白铁饥饿疗法治疗致死性细菌和真菌感染。
J Infect Dis. 2014 Jul 15;210(2):254-64. doi: 10.1093/infdis/jiu049. Epub 2014 Jan 19.
2
Dietary and prophylactic iron supplements : Helpful or harmful?膳食和预防性铁补充剂：有益还是有害？
Hum Nat. 1990 Mar;1(1):53-79. doi: 10.1007/BF02692146.
3
Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment.类风湿关节炎中的贫血：发病机制、诊断与治疗
Rheumatol Int. 1990;9(6):243-57. doi: 10.1007/BF00541320.
4
Drug antioxidant effects. A basis for drug selection?药物的抗氧化作用。药物选择的依据？
Drugs. 1991 Oct;42(4):569-605. doi: 10.2165/00003495-199142040-00003.
本文引用的文献
1
CARDIAC INVOLVEMENT IN COOLEY'S ANEMIA.库利贫血的心脏受累情况
Ann N Y Acad Sci. 1964 Oct 7;119:694-702. doi: 10.1111/j.1749-6632.1965.tb54070.x.
2
Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.吡哆醛异烟酰腙及其他吡哆醛亚氨基衍生物的体内铁螯合机制
J Lab Clin Med. 1981 Jul;98(1):99-108.
3
Survival and desferrioxamine in thalassaemia major.重型地中海贫血的生存与去铁胺治疗
Br Med J (Clin Res Ed). 1982 Apr 10;284(6322):1081-4. doi: 10.1136/bmj.284.6322.1081.
4
Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.酚类乙二胺衍生物：口服有效的铁螯合剂的研究
J Lab Clin Med. 1984 Mar;103(3):337-46.
5
Oxygen toxicity, oxygen radicals, transition metals and disease.氧中毒、氧自由基、过渡金属与疾病。
Biochem J. 1984 Apr 1;219(1):1-14. doi: 10.1042/bj2190001.
6
Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major.
Lancet. 1984 Feb 18;1(8373):392-3. doi: 10.1016/s0140-6736(84)90439-2.
7
Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload.吡哆醛复合物作为输血性铁过载口服治疗的潜在螯合剂。
J Pharm Pharmacol. 1982 Nov;34(11):730-2. doi: 10.1111/j.2042-7158.1982.tb06210.x.
8
Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.重型地中海贫血的长期螯合治疗：对肝脏铁浓度、肝脏组织学及临床进展的影响
Br Med J. 1974 Apr 6;2(5909):16-20. doi: 10.1136/bmj.2.5909.16.
9
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.皮下注射去铁胺对重型地中海贫血患者心脏病的预防作用
N Engl J Med. 1985 Jun 20;312(25):1600-3. doi: 10.1056/NEJM198506203122503.
10
Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
Br J Haematol. 1986 Apr;62(4):607-13. doi: 10.1111/j.1365-2141.1986.tb04082.x.
Zotero 插件